Molecular Partners AG
SIX:MOLN.SW
4.77 (CHF) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CHF.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 7.038 | 189.556 | 9.33 | 9.344 | 20.383 | 10.355 | 20.016 | 23.04 | 29.119 | 26.625 | 32.418 |
| Cost of Revenue
| 47.844 | 50.749 | 55.718 | 56.075 | 43.498 | 15.602 | 17.822 | 14.571 | 1.165 | 0.171 | 1.221 |
| Gross Profit
| -40.806 | 138.807 | -46.388 | -46.731 | -23.115 | -5.247 | 2.194 | 8.469 | 27.954 | 26.454 | 31.197 |
| Gross Profit Ratio
| -5.798 | 0.732 | -4.972 | -5.001 | -1.134 | -0.507 | 0.11 | 0.368 | 0.96 | 0.994 | 0.962 |
| Reseach & Development Expenses
| 46.731 | 50.749 | 55.718 | 56.075 | 43.498 | 38.203 | 37.453 | 35.185 | 23.918 | 18.793 | 20.821 |
| General & Administrative Expenses
| 18.995 | 21.822 | 16.906 | 11.027 | 13.164 | 9.462 | 8.281 | 7.238 | 6.221 | 4.899 | 3.591 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0.057 | 5.231 | 0 | 0 | 0 | 0 | 0 | 0.085 |
| SG&A
| 18.995 | 21.822 | 16.906 | 11.027 | 13.164 | 9.462 | 8.281 | 7.238 | 6.221 | 4.899 | 3.591 |
| Other Expenses
| 0 | 0.372 | 0.125 | 0.568 | 0.381 | 0.1 | 0.126 | 0.103 | 1.199 | 1.092 | 0.89 |
| Operating Expenses
| 65.726 | 72.943 | 72.749 | 67.67 | 57.043 | 47.765 | 45.86 | 42.526 | 31.337 | 24.784 | 25.301 |
| Operating Income
| -61.108 | 116.613 | -63.418 | -58.326 | -36.66 | -37.41 | -25.844 | -19.486 | -2.218 | 1.841 | 7.117 |
| Operating Income Ratio
| -8.683 | 0.615 | -6.797 | -6.242 | -1.799 | -3.613 | -1.291 | -0.846 | -0.076 | 0.069 | 0.22 |
| Total Other Income Expenses Net
| -0.876 | 1.24 | -0.365 | -4.449 | 0.389 | -0.218 | 0.001 | 0.628 | 1.783 | -4.461 | -0.202 |
| Income Before Tax
| -61.984 | 117.853 | -63.783 | -62.775 | -36.271 | -37.036 | -25.43 | -18.612 | -0.149 | -2.283 | 7.142 |
| Income Before Tax Ratio
| -8.807 | 0.622 | -6.836 | -6.718 | -1.779 | -3.577 | -1.27 | -0.808 | -0.005 | -0.086 | 0.22 |
| Income Tax Expense
| 2.252 | -0.717 | 0.002 | -0.011 | 0.017 | -0.156 | -0.001 | -0.628 | -1.783 | 4.461 | 0.202 |
| Net Income
| -61.984 | 117.853 | -63.785 | -62.764 | -36.288 | -37.036 | -25.43 | -18.612 | -0.149 | -2.283 | 7.142 |
| Net Income Ratio
| -8.807 | 0.622 | -6.837 | -6.717 | -1.78 | -3.577 | -1.27 | -0.808 | -0.005 | -0.086 | 0.22 |
| EPS
| -1.89 | 3.63 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.008 | -0.15 | 0.37 |
| EPS Diluted
| -1.89 | 3.54 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.008 | -0.15 | 0.37 |
| EBITDA
| -58.688 | 120.129 | -60.762 | -55.104 | -32.665 | -36.268 | -24.089 | -18.062 | -1.023 | 2.989 | 8.136 |
| EBITDA Ratio
| -8.339 | 0.634 | -6.513 | -5.897 | -1.603 | -3.502 | -1.203 | -0.784 | -0.035 | 0.112 | 0.251 |